WO2000037025A3 - Antibodies to truncated vegf-d and uses thereof - Google Patents

Antibodies to truncated vegf-d and uses thereof Download PDF

Info

Publication number
WO2000037025A3
WO2000037025A3 PCT/US1999/031332 US9931332W WO0037025A3 WO 2000037025 A3 WO2000037025 A3 WO 2000037025A3 US 9931332 W US9931332 W US 9931332W WO 0037025 A3 WO0037025 A3 WO 0037025A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
antibodies
vegfr
interfere
truncated vegf
Prior art date
Application number
PCT/US1999/031332
Other languages
French (fr)
Other versions
WO2000037025A2 (en
Inventor
Marc G Achen
Steven Alan Stacker
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Priority to DE69930872T priority Critical patent/DE69930872T8/en
Priority to AU33432/00A priority patent/AU770332B2/en
Priority to EP99969995A priority patent/EP1140175B1/en
Priority to CA002355896A priority patent/CA2355896A1/en
Priority to KR1020017007826A priority patent/KR20010081089A/en
Priority to JP2000589139A priority patent/JP4632543B2/en
Publication of WO2000037025A2 publication Critical patent/WO2000037025A2/en
Publication of WO2000037025A3 publication Critical patent/WO2000037025A3/en
Priority to HK01107909A priority patent/HK1038687A1/en
Priority to AU2004202080A priority patent/AU2004202080A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
PCT/US1999/031332 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof WO2000037025A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE69930872T DE69930872T8 (en) 1998-12-21 1999-12-21 ANTIBODIES AGAINST SHORTENED VEGF-D AND ITS USES
AU33432/00A AU770332B2 (en) 1998-12-21 1999-12-21 Antibodies to truncated VEGF-D and uses thereof
EP99969995A EP1140175B1 (en) 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof
CA002355896A CA2355896A1 (en) 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof
KR1020017007826A KR20010081089A (en) 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof
JP2000589139A JP4632543B2 (en) 1998-12-21 1999-12-21 Cleaved VEGF-D antibody and use thereof
HK01107909A HK1038687A1 (en) 1998-12-21 2001-11-09 Antibodies to truncated vegf-d and uses thereof
AU2004202080A AU2004202080A1 (en) 1998-12-21 2004-05-17 Antibodies to truncated VEGF-D and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11325498P 1998-12-21 1998-12-21
US13455699P 1999-05-17 1999-05-17
US60/134,556 1999-05-17
US60/113,254 1999-05-17

Publications (2)

Publication Number Publication Date
WO2000037025A2 WO2000037025A2 (en) 2000-06-29
WO2000037025A3 true WO2000037025A3 (en) 2000-11-16

Family

ID=26810852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/031332 WO2000037025A2 (en) 1998-12-21 1999-12-21 Antibodies to truncated vegf-d and uses thereof

Country Status (13)

Country Link
US (3) US6383484B1 (en)
EP (1) EP1140175B1 (en)
JP (1) JP4632543B2 (en)
KR (1) KR20010081089A (en)
CN (1) CN1330555A (en)
AT (1) ATE322909T1 (en)
AU (2) AU770332B2 (en)
CA (1) CA2355896A1 (en)
DE (1) DE69930872T8 (en)
DK (1) DK1140175T3 (en)
ES (1) ES2259247T3 (en)
PT (1) PT1140175E (en)
WO (1) WO2000037025A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
AU7142996A (en) * 1995-09-29 1997-04-28 Universita' Degli Studi Di Siena Regulated genes and uses thereof
DK0956339T3 (en) * 1996-08-23 2006-01-30 Licentia Oy Recombinant vascular endothelial cell growth factor D (VEGF-D)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
EP1248642A4 (en) * 2000-01-18 2005-05-18 Ludwig Inst Cancer Res Vegf-d/vegf-c/vegf peptidomimetic inhibitor
AU3988401A (en) * 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
ATE284701T1 (en) * 2000-03-02 2005-01-15 Ludwig Inst Cancer Res METHOD FOR TREATING TUMORS WHICH EXPRESS THE VASCULAR ENDOTHELIAL GROWTH FACTOR D
EP1299419A2 (en) * 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
ATE359300T1 (en) 2001-01-19 2007-05-15 Ludwig Inst Cancer Res FLT4 (VEGFR-3) AS A TARGET FOR CANCER DETECTION AND ANTI-CANCER TREATMENT
AU2002248467A1 (en) * 2001-02-12 2002-08-28 The Penn State Research Foundation Vegf-d expression in brain cancer
DE60236646D1 (en) * 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 antibodies
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
CN100497389C (en) 2001-06-13 2009-06-10 根马布股份公司 Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2003002144A1 (en) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US20060269548A1 (en) * 2001-07-12 2006-11-30 Kari Alitalo Lymphatic endothelial cells materials and methods
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2003252039A1 (en) * 2002-07-23 2004-02-09 Vegenics Limited Methods and compositions for activating or inhibiting vegf-d and vegf-c
US7608684B2 (en) * 2002-11-12 2009-10-27 Mochida Pharmaceuticals Co., Ltd. Soluble CD14 antigen
ATE460430T1 (en) * 2002-11-12 2010-03-15 Mochida Pharm Co Ltd KIT FOR EXAMINING HUMAN LOW MOLECULAR WEIGHT CD14 AND ANTIBODIES
DE10256410B3 (en) * 2002-12-02 2004-03-11 Daimlerchrysler Ag Energy management method for automobile air-conditioning device, has air-conditioning compressors controlled in dependence on assigned priorities upon detection of defined engine operating conditions
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
AU2004209668A1 (en) * 2003-02-04 2004-08-19 Flanders Interuniversity Institute For Biotechnology VEGF-B and PDGF modulation of stem cells
US20050043235A1 (en) * 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
US20050032697A1 (en) * 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
ES2388138T3 (en) 2003-08-27 2012-10-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
ES2396440T3 (en) 2006-01-18 2013-02-21 The General Hospital Corporation Methods of increasing lymphatic function
US7667880B2 (en) * 2006-02-10 2010-02-23 Adobe Systems, Incorporated Method and apparatus for previewing digital motion picture content
EP2125895B1 (en) * 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
AR066660A1 (en) * 2007-05-23 2009-09-02 Genentech Inc PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT
DE102007038730A1 (en) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Evidence of Human Vascular Endothelial Growth Factor
CN101245106B (en) * 2007-12-04 2011-07-20 澳赛尔斯生物技术（上海）有限公司 Anti-VRGF acceptor monoclone antibody, preparation method and application thereof
US7811776B2 (en) 2007-12-05 2010-10-12 University Of Cincinnati Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease
WO2009143584A1 (en) * 2008-05-30 2009-12-03 Vegenics Limited Treatment of pulmonary edema
SG10201510586PA (en) 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
JP2012517425A (en) * 2009-02-06 2012-08-02 ペプスキャン・システムズ・ベー・フェー Cleaved cystine knot protein
EP3243527B1 (en) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
JP2012522491A (en) * 2009-04-03 2012-09-27 ベジニクス ピーティーワイ リミテッド Anti-VEGF-D antibody
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
HRP20220399T1 (en) 2012-12-13 2022-05-13 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
CN105431204A (en) 2013-07-12 2016-03-23 奥普索特克公司 Methods for treating or preventing ophthalmological conditions
MX2016010683A (en) 2014-02-21 2017-05-11 Ibc Pharmaceuticals Inc Disease therapy by inducing immune response to trop-2 expressing cells.
CN106029098A (en) 2014-02-25 2016-10-12 免疫医疗公司 Humanized RFB4 anti-CD22 antibody
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN106999517A (en) 2014-10-07 2017-08-01 免疫医疗公司 The new adjuvant purposes of antibody drug conjugate
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
WO2016210108A1 (en) 2015-06-25 2016-12-29 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
SI3316885T1 (en) 2015-07-01 2021-09-30 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN109072241A (en) 2016-02-08 2018-12-21 维特里萨医疗公司 With the improved composition of vitreous half-life and application thereof
CN108794629A (en) * 2018-06-28 2018-11-13 浙江众意生物科技有限公司 A kind of VEGF-D monoclonal antibodies and kit
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
AU733322B2 (en) * 1996-07-15 2001-05-10 Chugai Seiyaku Kabushiki Kaisha Novel VEGF-like factor
KR100628697B1 (en) * 1997-12-24 2006-09-28 루드빅 인스티튜트 포 캔서 리서치 Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor

Also Published As

Publication number Publication date
CN1330555A (en) 2002-01-09
AU770332B2 (en) 2004-02-19
WO2000037025A2 (en) 2000-06-29
US7097986B2 (en) 2006-08-29
KR20010081089A (en) 2001-08-25
CA2355896A1 (en) 2000-06-29
ATE322909T1 (en) 2006-04-15
AU3343200A (en) 2000-07-12
PT1140175E (en) 2006-06-30
US6730489B1 (en) 2004-05-04
EP1140175A2 (en) 2001-10-10
DK1140175T3 (en) 2006-08-14
JP2002532113A (en) 2002-10-02
JP4632543B2 (en) 2011-02-16
DE69930872D1 (en) 2006-05-24
US20040141917A1 (en) 2004-07-22
AU2004202080A1 (en) 2004-06-10
DE69930872T8 (en) 2007-05-03
ES2259247T3 (en) 2006-09-16
DE69930872T2 (en) 2006-11-30
US6383484B1 (en) 2002-05-07
EP1140175A4 (en) 2003-03-05
EP1140175B1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
WO2000037025A3 (en) Antibodies to truncated vegf-d and uses thereof
DE69841273D1 (en) METHOD FOR IDENTIFYING BINDING DOMAINS THAT KEEP THEIR EPITOPHINENESS ABILITY
BR8606615A (en) COMPLEMENTARY POLIPEPTIDEOS TO PEPTIDEOS OR PROTEINS HAVING A SEQUENCE OF AMINO ACIDS OR NUCLEOTIDE CODING SEQUENCE KNOWN AT LEAST PARTIALLY AND DESIGN METHODS OF THE SAME
WO2002044215A3 (en) Hybrid antibodies
EP2141243A3 (en) Protein scaffolds for antibody mimics and other binding proteins
DE69522216T2 (en) Target cell-binding chimeric peptides
CA2111645A1 (en) Fibrinogen fragment e peptides and antibodies thereto
NO986088D0 (en) Polypeptides with the ability to form antigen binding structures with specificity
WO2001064877A3 (en) Human schizophrenia gene
ATE327328T1 (en) ADIPOCYTE-SPECIFIC PROTEIN HOMOLOGUE
ES2072868T3 (en) PROTEIN ABLE TO BIND FIBRONECTIN AND ITS PREPARATION.
ATE542138T1 (en) HER-2 BINDING ANTAGONISTS
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
EP1780219A3 (en) Protein S polypeptides and uses thereof
WO2001064876A3 (en) Human schizophrenia gene
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
CA2112701A1 (en) Proteins s polypeptides and uses thereof
WO2003033675A3 (en) Identification of binding partners for specific proteins
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
DK0889907T3 (en) Monoclonal antibodies that bind human growth hormone (hGH)
WO1998031796A8 (en) Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
GB2286189A (en) Recombinant specific binding protein
GB2333295A (en) Modified protein G and fragments thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814571.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 33432/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2355896

Country of ref document: CA

Ref document number: 2355896

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017007826

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 589139

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999969995

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017007826

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999969995

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 33432/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999969995

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017007826

Country of ref document: KR